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Abstract 
Background: Data regarding the evolution of antimicrobial resistance are needed to suggest appropriate empirical treatment of 
urinary tract infections (UTI) in developing countries. To assess the antimicrobial susceptibility of Escherichia coli, the 
predominant pathogen in community-acquired UTI, a prospective multicenter study was carried out in Dakar, Senegal. 
Methodology: From February 2004 to October 2006, 1010 non-duplicate E. coli strains were collected from four centres. 
Antimicrobial susceptibility testing was performed using disk diffusion method according to the recommendations of the CA-SFM 
(2004). 
Results: Most of the isolates were resistant to amoxicillin (73.1%), amoxicillin-clavulanic acid (67.5%), cephalothin (55.8%), and 
trimethoprim/sulfamethoxazole (68.1%). Extended spectrum beta-lactamase was detected in 38 strains. The overall resistance 
rates to nalidixic acid, norfloxacin and ciprofloxacin were 23.9%, 16.4% and 15.5%, respectively. Most of the strains were 
susceptible to gentamicin, nitrofurantoin and fosfomycin (respective susceptibility rates, 93.8%, 89.9%, and 99.3%). During this 
period, a significant decrease in sensitivity was observed for cephalothin, fluoroquinolones and trimethoprim/sulfamethoxazole 
(p<0.001). 
Conclusions: These data suggest that trimethoprim/sulfamethoxazole may no longer be used as empirical treatment for 
community-acquired UTI in Dakar. In order to preserve the activity of fluoroquinolones for future years, alternatives such as 
fosfomycin or nitrofurantoin should be considered. 
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Introduction 
Symptomatic urinary tract infection (UTI) is one 
of the most commonly diagnosed infections in 
communities, particularly in otherwise healthy 
young women. Several studies conducted in 
Europe and in the USA have reported a steady 
increase of the resistance rate of uropathogens to 
commonly prescribed antibiotics (amoxicillin, 
trimethoprim-sulfamethoxazole), reducing 
therapeutic possibilities [1-3]. In some countries, 
resistance to fluoroquinolones is also emerging [4]. 
In developing countries, the frequently irrational 
use of antibiotics predicts a worrisome increase in 
the prevalence of antimicrobial resistance. 
Worldwide, Escherichia coli has been 
established as the most commonly isolated 
pathogen among organisms implicated in 
community-acquired UTI. In Senegal the same 
situation prevails [5]. Hence, a prospective three-
year study was undertaken, from February 2004 to 
October 2006, to determine the susceptibility 
patterns of E. coli strains isolated from outpatients 
referred from four clinical laboratories located in 
Dakar, the capital of Senegal. 
 
Materials and Methods 
Patients 
From February 2004 to October 2006, a total 
of 1010 E. coli strains isolated from the urine of 
patients with community-acquired urinary tract 
infections was collected from four clinical 
laboratories in Dakar. Two of these laboratories 
(Institut Pasteur, Bio24) are private institutions 
receiving patients referred by general practitioners. 
The two others are located inside hospitals, one 
being a major teaching hospital (Hôpital Aristide Le 
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Dantec) and the other a military hospital (Hôpital 
Principal). These hospital laboratories recruited 
subjects examined in the outpatients department 
with a suspected diagnosis of UTI. The patients 
attending the private laboratories, as well as the 
military hospital, belonged to upper and middle 
classes, while the majority of samples examined in 
the teaching hospital belonged to patients from the 
underprivileged classes. Pregnant women aged 
between 15 and 45 years were recorded. Patients 
were questioned about some specific conditions 
(i.e. hospitalization, antibiotic treatment, UTI and 
urinary catheterization) that could have occurred 
during the month preceding the onset of the 
symptoms. The nature of previously prescribed 
drugs was not included in the statistical analysis 
because very few patients were able to name the 
prior antibiotic used precisely.  
 
Bacterial strains 
Leukocyte count, isolation and identification of 
bacteria were conducted on site from urine 
samples by all the laboratories as part of their 
routine diagnostic. Only a pure culture of E. coli 
with a colony count of ≥ 105 cfu/ml associated with 
pyuria (WBC ≥ 104 / ml) was considered significant 
for inclusion. All E. coli isolates were collected for 
antimicrobial susceptibility testing by the 
coordinating laboratory located in Institut Pasteur. 
Species identification was checked by inoculation 
onto a culture medium allowing differentiation of 
main uropathogens (Chromagar orientation 
medium, Becton-Dickinson, Heidelberg, Germany). 
According to the manufacturer’s instructions, 
indole-positive, pink-coloured colonies were 
confirmed as E. coli. In case of uncertainty, clear 
identification was performed using API 20E gallery 
(bioMérieux, Marcy l’Etoile, France). 
 
Antimicrobial susceptibility testing 
Antibiotics’ susceptibility was performed by 
disk diffusion method according to the guidelines 
of the Antibiogram Committee of the French 
Society for Microbiology (CA-SFM) [6]. Antibiotic 
disks were obtained from Bio-Rad laboratories 
(Marnes-la-Coquette, France) and strains were 
tested against the following antimicrobial agents 
(quantity of antibiotic per disk): amoxicillin (10 µg), 
amoxicillin-clavulanic acid (20 µg/10 µg), ticarcillin 
(75 µg), cephalothin (30 µg), cefotaxime (30 µg), 
ceftazidime (30 µg), nalidixic acid (30 µg), 
norfloxacin (5 µg), ciprofloxacin (5 µg), 
trimethoprim/sulfamethoxazole (cotrimoxazole) 
(1.25 µg/23.75 µg), gentamicin (15 µg), 
nitrofurantoin (300 µg), and fosfomycin (50 µg). 
Extended spectrum beta-lactamase (ESBL) 
producing organisms were detected by the double-
diffusion method looking for synergy images 
between amoxicillin-clavulanic acid and 
cefotaxime, or ceftazidime disks. Isolates 
producing ESBL were considered to be resistant to 
cefotaxime and ceftazidime according to the CA-
SFM recommendations. Inhibition zone diameters 
were measured with an automated zone size 
reader (Osiris, Bio-Rad) and isolates were 
classified as susceptible, intermediate or resistant 
according to the annual report of the CA-SFM [6]. 
Intermediate and resistant strains were further 
grouped together in the resistant group for 
analysis. E coli ATCC 25922 was used as the 
control strain.  
 
Statistical analysis 
Statistical analysis was performed using 
STATA software version 6.0. Risk factors 
predicting E. coli resistance were estimated by 
univariate analysis and tested when appropriate by 
χ2 or Fisher's exact test. Variables with P < 0.25 in 
the univariate analysis were then included in a 
multivariable logistic regression model. Variables 
with an adjusted odds ratio of P < 0.05 were 
considered as risk factors.  
 
Results 
One thousand and ten non-duplicate E. coli 
strains (561 from Institut Pasteur, 225 from Bio24, 
177 from the teaching hospital laboratory, 47 from 
the military hospital laboratory), were collected 
during the study period. Seven hundred and 
seventy strains (76.3%) were isolated from women 
and 239 (23.7%) from men (sex status unknown 
for 1 patient). Patients were classified in three 
categories according to age: patients under 15 
years (115;11.5%), patients aged from 15 to 50 
years (635;63.6%) and patients over 50 years 
(249;24.9%), data was not available for 11 patients 
(1.1%). Among women aged from 15 to 45 years, 
16.7% (84/504) were pregnant. The percentage of 
patients presenting potential risk factors for 
antimicrobial resistance was recorded as follows: 
hospitalization (4.6%, data reported for 940 
patients), antibiotic exposure (16.4% of 971 
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patients), UTI (9.6% of 948 patients) and urinary 
catheterization (2.4% of 918 patients). Missing 
data were due to the difficulty in collecting oral 
information from some patients. 
Resistance rates of E. coli strains to selected 
antimicrobial agents by year of study are 
presented in Table 1.  
 
Table 1. Antimicrobial resistance of E. coli isolates from 
community acquired urinary tract infections by antibiotic 
and year of study. 
 No. of isolates resistant to antibiotics (%) 
Year (no. 
isolated) 
2004 
(289) 
2005 
(449) 
2006 
(272) 
Total 
(1010) 
AMX 208 (72.0) 
323 
(71.9) 
207 
(76.1) 
738 
(73.1) 
AMC 186 (64.4) 
302 
(67.3) 
194 
(71.3) 
682 
(67.5) 
TIC 190 (65.7) 
307 
(68.4) 
190 
(69.9) 
687 
(68.0) 
CF 134 (46.4) 
254 
(56.6) 
176 
(64.7) 
564 
(55.8) 
CTX 8  (2.8) 
13  
(2.9) 
14  
(5.2) 
35  
(3.5) 
CAZ 10  (3.5) 
15  
(3.3) 
13  
(4.8) 
38  
(3.8) 
NA 58 (20.1) 
110 
(24.5) 
73 
(26.8) 
241 
(23.9) 
NOR 31 (10.7) 
72  
(16.0) 
63 
(23.2) 
166 
(16.4) 
CIP 28  (9.7) 
69  
(15.4) 
60 
(22.1) 
157 
(15.5) 
SXT 169 (58.5) 
323 
(71.9) 
196 
(72.1) 
688 
(68.1) 
GE 16  (5.5) 
22  
(4.9) 
25  
(9.2) 
63  
(6.2) 
FUR 27  (9.5) 
45  
(10.0) 
30 
(11.0) 
102 
(10.1) 
FOS 4  (1.4) 
1  
(0.2) 
2  
(0.7) 
7  
(0.7) 
 
AMX, amoxicillin; AMC, amoxicillin-clavulanic acid; TIC, ticarcillin; CF, cephalothin; CTX, 
cefotaxime; CAZ, ceftazidime; NA, nalidixic acid; NOR, norfloxacin; CIP ciprofloxacin; SXT, 
trimethoprim/sulfamethoxazole (cotrimoxazole); GE, gentamicin; FUR, nitrofurantoin; FOS, 
fosfomycin. 
 
The majority of the isolates were resistant to 
amoxicillin, amoxicillin-clavulanic acid, ticarcillin 
and first generation cephalosporins (respective 
overall resistance rates: 73.1%, 67.5%, 68% and 
55.8%). Third generation cephalosporins 
(cefotaxime, ceftazidime) remained active in most 
cases (respective overall resistance rates: 3.5% 
and 3.8%). ESBL was detected in 38 strains 
(3.8%): 14 strains in 2004 (4.8%), 12 strains in 
2005 (2.7%), and 12 strains in 2006 (4.4%). A high 
resistance rate was found for cotrimoxazole 
(68.1%). As for quinolones, 23.9% of the strains 
were resistant to nalidixic acid, 15.5% to 
ciprofloxacin and 16.4% to norfloxacin. Most of the 
strains were susceptible to gentamicin (93.8% 
susceptible) and nitrofurantoin (89.9% 
susceptible). Almost all strains were susceptible to 
fosfomycin (99.3% susceptible). 
During this study, a significant increase was 
observed for resistance to cephalothin (P<0.001), 
norfloxacin (P<0.001), ciprofloxacin (P<0.001) and 
cotrimoxazole (P<0.001). According to multivariate 
analysis (Table 2), age > 50 years was identified 
as a risk factor for resistance to nalidixic acid, 
norfloxacin and ciprofloxacin.  
 
Table 2. Variables statistically related to antimicrobial 
resistance in the multivariate model. 
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Male gender was significantly linked to a 
higher rate of resistance to gentamicin and third 
generation cephalosporins (cefotaxime, 
ceftazidime). Antibiotic exposure within the month 
before infection was significantly associated with 
resistance to amoxicillin, nalidixic acid, 
ciprofloxacin, cotrimoxazole and approached 
significant resistance to norfloxacin (P=0.05). 
Within the same period, previous hospitalization, 
prior UTI, and prior urinary catheterization were 
not considered in our model to be risk factors of 
antimicrobial resistance to any of the tested drugs. 
 
Discussion 
Antimicrobial susceptibility testing of 
uropathogens is known to overestimate rates of 
resistance because antibiograms are performed 
mostly if empirical treatment fails, or if patients 
have underlying factors [7]. In developing 
countries, this bias may be more present because 
many patients cannot afford medical expenses, so 
they undergo urine analysis only in case of 
repeated or complicated UTI. Nevertheless, this 
study confirms that levels of antimicrobial 
resistance of outpatient E. coli urinary isolates to 
aminopenicillins, cotrimoxazole and 
fluoroquinolones are higher in Dakar than those 
observed in Europe and North America [1,2]. This 
is consistent with recent data reported in other 
developing countries [8-11]. 
Previous data collected in our laboratory 
[5,12,13] confirm the steady decrease in 
susceptibility of E. coli strains isolated from 
community-acquired UTI to amoxicillin-clavulanic 
acid, cephalothin, quinolones, and cotrimoxazole 
since 1999. To date, cotrimoxazole is still 
recommended by Senegalese health authorities as 
the first line treatment for UTI in primary health 
care structures, which can explain the high level of 
resistance rate observed in this study. The 
significant increase of resistance to quinolones, 
and the high resistance rates reached in 2006, are 
worrisome and could be related to the easy access 
and the misuse of this class of antibiotics in 
Senegal [13]. Another factor could be the 
generalized use of fluoroquinolones in animal feed 
in the country (especially in poultry intensive 
breeding), and the subsequent transmission of 
resistant strains from animals to humans [14]. 
Accuracy of the risk factors analysis must be 
put into perspective because information was 
obtained directly from patients without checking 
their medical reports. Nevertheless, multivariate 
analysis highlighted some specific risk factors. 
Antibiotic exposure a month before infection was 
reported by multivariate analysis as a risk factor for 
resistance to amoxicillin, nalidixic acid, 
ciprofloxacin, and cotrimoxazole. This data 
partially confirms a previous study conducted in 
our laboratory, when antibiotic exposure within the 
previous six months was found associated with 
resistance to amoxicillin, amoxicillin-clavulanic acid 
and cotrimoxazole [13]. In our study, age over 50 
years and male gender were found statistically 
significant with resistance to fluoroquinolones by 
univariate analysis (P<0.01). This result has been 
previously reported and could be related to the 
tendency for male or elderly patients to be infected 
by more resistant strains because they are more 
likely to present complicated urinary tract 
infections [15]. In our multivariate model, if age > 
50 years remained independently associated with 
resistance to fluoroquinolones (P<0.001), male 
gender did not. In addition, a significant 
relationship has been found between male gender 
and resistance to third generation cephalosporins 
and gentamicin. To our knowledge, association to 
male gender has not been previously recorded for 
these antibiotics. 
Aminopenicillins or cotrimoxazole should no 
longer be used as empirical treatments of UTI in 
Senegal. Alternatives must be recommended, 
especially for empirical treatments of 
uncomplicated UTI (cystitis) in women. Although 
most E. coli isolates were susceptible to 
nitrofurantoin, this antimicrobial agent has 
demonstrated poor in vitro activity against 
Enterobacteriaceae other than E. coli [16]. 
Moreover, this antibiotic does not penetrate into 
tissues and could not be used to treat infections 
with suspected tissue involvement (such as 
pyelonephritis). Generalized prescription of 
fluoroquinolones as empirical treatment for cystitis 
should be abandoned. This common practice 
facilitates the emergence of strains resistant to this 
class of antibiotics and promotes the emergence of 
multidrug-resistant strains in the community [17]. A 
substantial effort has to be made in Senegal to 
protect the activity of fluoroquinolones by 
controlling their prescription in human medicine 
and limiting (or even banning) their use in animal 
husbandry. 
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A previous study conducted in Dakar has 
shown that resistance rates of Enterobacteriaceae 
to fosfomycin-trometamol, a form of fosfomycin 
characterized by a high oral biodisponibility, was 
very low [18]. Our data about E. coli confirm these 
findings. Fosfomycin-trometamol has been 
proposed as a reliable empirical treatment for 
uncomplicated UTI because of its easy use (single 
dose), its good tolerance, and its efficacy [19]. 
Although in vitro resistance to fosfomycin is easily 
acquired by multiple one-step mutations, treatment 
failures are rare. A recent study suggests that the 
biological fitness of these resistant mutants is 
affected, so they are less likely to infect the 
bladder [20]. Unfortunately, this antibiotic is not yet 
available in Senegal. However, to preserve the 
efficacy of fluoroquinolones, we suggest that 
fosfomycin could be an option for empirical 
treatment of urinary tract infections in outpatients, 
and should be introduced into the national 
guidelines. 
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